Analyst: Vycor Medical Attractive Going into 2015 On Key Value Drivers
Vycor Medical (OTCBB: VYCO) is a fast-growing device company with two FDA-cleared products that could drive shareholder value much the same way Organovo (NYSE MKT: ONVO), Antares (NASDAQ: ATRS) and Neuralstem (NYSE MKT: CUR) have – by addressing large, unmet and growing needs for better patient outcomes.
Vycor’s products address an estimated $700 Million market in neurosurgery; and greater than $2 Billion in vision loss as a result of stroke, whereas the Company is valued at just $22M. Vycor has grown sales at a 52%+ clip compounded over 5 years with 85%+ gross margins. Expansion of the Company’s neurosurgical product line, launch of vision restoration therapy and a digital equivalent of existing compensation therapies in rehab centers - alongside new and potential distributor relationships globally - will be crucial drivers of growth.
In his initiation report, On the Cusp of the Next Big Healthcare Trend, Senior Equity Analyst Dante Ruffalo, a former biomedical research scientist and patent attorney, reveals why Vycor could see tremendous upside in 2015. His reasoning includes best-in-class products for large, unabated markets where little competition exists and barriers to entry for competitors are high; an attractively valued equity; and alignment of shareholder and management interests due to a large personal investment in the Company by senior executives. A change at the highest executive position earlier this year adds fuel to the potential for unlocking shareholder value.
To Access Mr. Ruffalo’s Initiation Report on Vycor Medical, visit OneEquityResearch.com
About Dante Ruffalo
Dante Ruffalo is a former biomedical research scientist published in Neuroscience and Psychophysiology. Mr. Ruffalo is also a patent attorney, an economic advisor and a research fellow at a Eurasian think tank where he collaborates with European counter parties in writing white papers that seek to advance science curricula. Mr. Ruffalo is a member of the high IQ society Mensa and writes Mensa's economics column for their monthly publication.
About One Equity Research
One Equity Research is a leading provider of proprietary and in-depth research crafted by respected financial analysts and domain experts. Our team includes trained finance professionals with diverse backgrounds that include equity research, investment banking, and strategic consulting at preeminent firms. We distribute our research through mainstream media partners and to subscribers of our Intelligence Service.
Legal Disclaimer
The report described in this press release has been prepared by One Equity Research, LLC on behalf of Vycor Medical, Inc. (the "Company"), as part of investor relations services provided to Vycor Medical by One Equity Research. One Equity Research has been compensated ten thousand dollars per month for a period of up to four months for ongoing research coverage as fully disclosed on One Equity Research. Dante Ruffalo is the author of the report and the views regarding Vycor Medical expressed in the report accurately reflect the personal views of Mr. Ruffalo regarding Vycor Medical and its securities, as of the date of the report. The research report is not an offer or solicitation to buy or sell the securities of Vycor Medical. The report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation.
Contact
Dante F. Ruffalo, JD
Senior Equity Analyst
+1.913.579.2071
[email protected]
